NCT07283692RecruitingPhase 2
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 4 Dec 2025
- Start date
- 1 Mar 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- RenJi Hospital
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT07283692
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From 1 Mar 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Metastatic disease (Stage IV)
Age
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Who the study is looking for
- Female, Aged ≥18 and ≤70 years
- Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative)
- Subjects with at least one evaluable lesion
- ECOG 0-1
- Adequate organ function
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.